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Renewed interest in the 
polyphosphoinositides 
Stephen K. Fisher, Lucio A. A. Van Rooijen and 
Bernard W. Agranoff 
The significance o f  the enhanced cellular phosphatidate and phosphatidylinositol 
turnover which occurs in response to specific extracellular messengers has been the 
subject o f  much  interest and  speculation. Until recently, much  less attention has been 
pa id  to the presence o f  two quantitatively minor  phosphorylated derivatives o f  
phosphatidylinositol,  k n o w n  collectively as the polyphosphoinositides.  These lipids 
have an extremely rapid ~V2p turnover rate and are presumed  to be localized 
predominant ly  in the p lasma membranes .  Their turnover now  appears to be l inked 
with that o f  phosphatidate and phosphatidylinositol,  and  is discussed here in relation 
to the consequences o f  l igand-receptor interactions. 
Polypbosphoinositides as cell membrane 
components 
Phosphatidylinositol  (Phl) ,  as well as 
two phosphoryla ted derivatives, phos- 
phatidylinositol 4-phosphate (PhIP) and 
phosphatidylinositol 4,5-bisphosphate 
(PhlP2), are found in eukaryotic mem- 
branes (see Fig. 1). Because of  the 
highly polar nature of these lipids, their 
quantitative extraction from tissues 
usually requires conditions of  acidity or 
high ionic strength,  and special thin 
layer chromatographic  procedures  are 
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needed  for their separation. These two 
factors may explain much of  the past 
neglect of  ligand-stimulated turnover of 
the polyphosphoinosit ides.  A n  even 
more  important  factor is their rapid 
resynthesis, such that lipid breakdown 
can go unnoticed if it is not measured 
within seconds of ligand addition. 
Subcellular distribution and metabolism 
PhlP  and PhlP2 are synthesized from 
endogenous  Phl  via sequential phos- 
phorylation by A T P  at the D-4 and D-5 
positions of  the myo-inositol  moiety, 
under  the action of  specific kinases. In 
turn, phosphomonoesterases can dephos- 
phorylate PhIP2 to PhIP and PhIP to 
Phi.  The combined effects of the kinases 
and monoesterases  result in the rapid 
equilibration of  radioactivity in the 
gamma position of  ATP with that of  the 
inositide monoes ter  functions. Alterna- 
tively, the entire headgroup of  the poly- 
phosphoinosit ides can be removed via 
phosphodiesterat ic  cleavage of the 
phospholipase C variety to yield the 
apolar product ,  diacylglycerol ( D A G ) ,  
together  with inositol bis- or trisphos- 
phate  from PhlP  or PhlP2, respectively. 
Available information from subcellular 
fractionation studies suggests that most 
of  the relevant enzymes of  polyphos- 
phoinositide metabolism are present  in 
both  the plasma membrane  and in the 
cytosol 2. The ability to form labeled 
PhlP2 from endogenous  Ph lP  and 
[.,/.32p] A T P  is a convenient  measure 
of  PhIP kinase, and has been demon-  
strated in purified plasma membrane  
preparat ions,  as well as in plasma mem- 
brane-enriched tissues, e.g. brain, kid- 
ney, polymorphonuclear  leukocytes and 
erythyrocytes 2. However ,  Phi  kinase 
and/or PhIP kinase activity has also 
been documented  in adrenal chromaffin 
granules, mitochondria ,  lysosomes, 
Golgi preparat ions and the nuclear en- 
velope. Phi  and PhlP  kinases are Mg 2+- 
dependent ,  while the effects of Mg 2÷ 
and Ca 2÷ on the lipid phosphomono-  
esterase activities appear to vary with 
the tissue source of the enzyme. There  
is general agreement  that Ca 2÷ ions at 
miUimolar concentrations selectively acti- 
vate the phosphodiesterase(s) ,  although 
the optimal concentrat ion appears to 
depend  upon the assay conditions em- 
ployed. The enzymatic potential  for 
degradation of the polyphosphoinositides 
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in brain exceeds that of synthesis by one 
or two orders of magnitude, the most 
active being an apparent 'phospholipase 
C' phosphodiesteratic activity. Other 
possible pathways for polyphosphoinosi- 
tide degradation, for example via phos- 
pholipase D or A2 activity, are minor. It 
thus appears that the breakdown of 
polyphosphoinositides via a type C 
phosphodiesteratic cleavage is likely to 
be of most physiological significance. 
Receptors coupled to polyphosphoinosi- 
tide turnover 
The Hokins first demonstrated that 
activation of certain receptors (e.g. 
muscarinic chollnergic or oq-adrenergic) 
resulted in increased incorporation of 
added 32p i in to  phosphatidate (PhA) 
and Phi. It was subsequently reported 
that there was a net loss of Phi upon 
stimulation with the accumulation of an 
approximately equivalent amount of 
PhA 3. This was thought to arise from an 
initial phosphodiesteratic breakdown of 
Phi, liberating DAG which was in turn 
O 
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Fig. l. The structure of phosphatidylinositol 4,5- 
bisphosphate (PhlP2). Phosphatidylinositol (Phi) 
is phosphodiesterified at D-1 of myo-inositol, and 
has no phosphomonoester substituents, while phos- 
phatidylinositol 4-phosphate (PhIP) is phosphory- 
lated only at the D-4 position. Phi, PhlP and 
PhlP2 are also commonly abbreviated as MPI, 
DPI and TPI (for mono-, di- and triphosphoinosi- 
tide). The IUB-IUPAC recommended abbrevia- 
tions are, respectively, Ptdlns, Ptdlns4P and 
Ptdlns(4,5)P2. These latter abbreviations, how- 
ever, have been the subject of  some confusion 
related to their correct structural assignments # . In 
each of  the three inositides, the phosphodiesteratic- 
ally-linked 1,2-diacyl-sn-glycero-3-phosphate is 
enriched in the 1-stearoyl, 2-arachidonoyl species. 
The possibility that the inositol lipids serve as a 
reserCoir of  arachidonate for prostanoid synthesis 
has been proposed, although it is not yet clear 
which inositide or inositide-related lipid is the 
donor. In this paper, myo-inositol tg-l-phosphate, 
myo-inositol-o-l , 4-bisphosphate and myo-inositol- 
D-l,4,5-trisphosphate are referred to as IP#, lP2 
and IP,. 
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TABLE I. Receptors coupled to polyphosphoinositide turnover in target tissues 
Tissue Receptor Refs 




Brain (nerve ending 
preparations or slices) 
Avian salt gland 
Blowfly salivary gland 
Adrenal gland 
Pancreas 
Muscarinic cholinergic, al-adrenergic 6 
Vasopressin, angiotensin 7, 8 
Muscarinic chofinergic, oq-adrenergic, 
substance P 9, 10 
Thrombin, ADP, platelet activating factor 11-14 
Muscarinic cholinergic, ACTH 10, 15, 16 
Muscarinic cholinergic 17 
5-HT~ 10 
ACI~ 18 
Muscarinic cholinergic, caerulein 19 
rapidly rephosphorylated in the pres- 
ence of [32p]ATP to yield [32p]PhA. 
The PhA was then proposed to be con- 
verted to Phi via (CDP-DAG)*, complet- 
ing a 'phosphatidate-phosphatidylinositol 
cycle' (Fig. 2). The vast number of 
studies on stimulated incorporation of 
32p i into PhA and Phi or of [3H]inositol 
into Phi are thus several steps away 
from the presumed site of receptor- 
ligand action, i.e. phosphodiesteratic 
cleavage. In an early study, Durell et 
al. 4 noted a possible increased production 
of inositol bisphosphate, under condi- 
tions of stimulation of brain homogenate 
with acetylcholine. Despite this observa- 
tion, and the known metabolic interrela- 
tionships between the inositol lipids, a 
direct effect of receptor activation on 
PhIP and PhIP2 turnover was not pro- 
posed or examined further until 1977, 
when Abdel-Latif and colleagues demon- 
strated that exposure of the iris smooth 
muscle to acetylcholine resulted in in- 
creased breakdown of 32p-prelabeled 
PhIP2 (Ref. 5). These experiments, as 
well as a number of other indirect indi- 
cations, led to intensified efforts to iden- 
tify changes in polyphosphoinositides 
associated with receptor activation. 
There are by now numerous documented 
examples of receptor-ligand interaction 
linked to polyphosphoinositide turnover 
(Table I). In most instances, this has 
been measured by loss of polyphospho- 
inositide radioactivity from [3H]inositol 
or 32p-prelabeled cells. Such studies 
indicate that radiolabeled PhIP2, and in 
some instances PhIP as well, is rapidly 
diminished following addition of a speci- 
fic ligand. For example, 20% or more of 
label in PhIP2 is lost within 5-30 s of 
exposure of platelets to thrombin, of 
hepatocytes to vasopressin, or of parotid 
gland slices to methacholine. There is 
evidence in the iris smooth muscle, in 
platelets, and in blowfly salivary gland 
for the simultaneous release of inositol 
trisphosphate, a result consistent with 
*CDP-DAG = cytidine diphosphadiacyl glyccrol. 
the phosphodiesteratic cleavage of PhlP2 
following receptor activation. The 
rapidity with which the lipid breaks 
down following ligand addition suggests 
that the cleavage of PhIP2 rather than of 
Phi constitutes the initial event follow- 
ing receptor activation and that the dis- 
appearance of Phi is a secondary 
response which reflects the process of 
replenishment of the depleted polyphos- 
phoinositide pool. 
Of potential relevance are recent 
studies with isolated synaptic membranes. 
Gispen and colleagues have shown that 
the addition of adrenocorticotropin 
(ACTH) to these preparations results in 
an increase in polyphosphoinositide 
labeling 15. The effects are interpreted 
to reflect increased phosphorylation of 
PhlP to PhlP2. The presumed mechan- 
ism is inhibition by ACTH of the phos- 
phorylation of a membrane protein of 
about M r 48 000 ('B50') whose phos- 
phorylated form inhibits PhlP kinase. 
The B50 kinase is thought to be similar 
or perhaps identical to protein kinase C, 
found commonly in the cytosol of a 
number of tissues, particularly brain. 
While the protein kinase C is isolated 
from the cytosol and the B50 kinase is 
membrane-bound, free and bound forms 
of protein kinase C have been found in 
cultured cells, and their ratio is reportedly 
altered by the presence of phorbol 
esters 2°. ACTH administration, both in 
v ivo  and in vitro,  results in a rapid 
increase in the chemical amounts of 
both PhlP and PhlP2 in the adrenal, 
with a time course similar to that re- 
ported for corticosterone production ~s. 
Direct additions of PhlP and PhlP2 to 
adrenal mitochondria "are reported to 
increase the rate of side chain cleavage 
of cholesterol to form pregnenolone, a 
result suggesting that the polyphospho- 
inositides play a significant role in 
steroidogenesis. 
Calcium and the polyphosphoinositides 
Since many receptor-ligand actions 
that affect polyphosphoinositide turn- 
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Fig. 2. Cyclic turnover of inositol lipids. The originally proposed cycle (upper left) of Phi ~> DA G -> 
PhA ->  CDP-DAG -> Phi is now extended to include the polyphosphoinositides. While phosphodiester- 
atic cleavage of PhlP is indicated, there is better evidence for stimulated Phil', breakdown following 
receptor-ligand (RL) activation. The cycle on the right demonstrates the sequential breakdown of lp~ to 
inositol. The breakdown of IP 1 is blocked by Li +. Cellular inositol is supplied exogenously (I~ 0 or 
produced by degradation of L-myo-inositol phosphate (IP~) formed via cyclization o( glucose-6-phosphatc 
(G6P). 
over exert their physiological effects by 
increasing intracellular Ca 2+, it is not 
surprising that a direct role for Ca 2+ in 
the metabolism, of these phospholipids 
has also been proposed. Central to this 
issue is the question of whether the 
increased lipid turnover either (1) is the 
consequence of an increase in cytosolic 
Ca z+, (2) mediates the increase in Ca 2+ 
permeability, or (3) parallels, but is 
independent of, Ca 2+ mobilization. In 
support of the first possibility is the 
finding that the muscarinic cholinergic 
or oq-adrenergic stimulated breakdown 
of PhIP2 in iris smooth muscle requires 
added Ca 2+, is abolished ir~ the pres- 
ence of EGTA or inhib,ors of Ca 2+ 
translocation, a ¢ .: can be induced by the 
addition of Ca 2+ ionophores 6. In hepato- 
cytes, vasopressin stimulation of PhIP2 
breakdown is abolished in the presence 
of EGTA 7. Furthermore, the introduc- 
tion of C a  2+ into a nerve ending 
preparation with the divalent cation 
ionophore A23187 stimulates the break- 
down of PhIP and PhIP2, under condi- 
tions in which inositol phosphates accu- 
mulate 2~. On the other hand, the 
stimulated breakdown of PhIP2 in the 
parotid gland, platelet and pancreas ap- 
pears insensitive to Ca 2+ depletion, or is 
at least less so than the attendant physio- 
logical responses. This latter result sup- 
ports the second possibility, namely that 
PhIP2 breakdown reflects a molecular 
mechanism whereby cells gate Ca 2+, so 
that increased turnover of PhIP2 is not 
regulated by the increase in intracellular 
Ca 2+. An alternative explanation is that 
Q 
these cells are not easily depleted of 
Ca 2+ in the presence of extraceUular 
EGTA. The various results, taken 
together, are compatible with the inter- 
pretation that polyphosphoinositide 
turnover is Ca2+-dependent, but may 
not be Ca2+-regulated. 
Because of the known high affinity of 
polyphosphoinositides for binding Ca 2+ 
ions, their plasma membrane localiza- 
tion and potential for rapid degradation 
upon receptor activation, these lipids 
have been considered as a possible res- 
ervoir of cell Ca 2+. It has been demon- 
strated that the Ca2+-binding activity of 
erythrocytes increases directly with the 
state of inositide phosphorylation 22. 
Similarly, phosphorylation of renal 
brush border membrane vesicles results 
in stimulation of Ca 2+ intake, with in- 
creased phosphoinositide and PhA con- 
tent 23. It is less certain, however, that 
the chemical amounts of Ca 2+ bound to 
polyphosphoinositides suffice to account 
for the increase in cytosolic Ca 2+ resul- 
ting from receptor activation. Calcula- 
tions of amounts of Ca 2+ released from 
PhlP2 in hormone-stimulated hepato- 
cytes indicate that only a small fraction 
of the measured Ca 2+ released from 
these cells could be derived from the 
polyphosphoinositide pool. In the case 
of platelets, the calculated amounts of 
Ca 2+ released from PhlP 2 following 
ADP addition could, however, account 
for an increase in intracellular Ca 2+ by 
10 pI,M 13. These observations must be 
tempered by considerations of condi- 
tions in v ivo .  For example, these various 
55 
calculations assume that Ca 2+ is the sole 
cation present. Although cytosolic Mg 2+ 
is in fact present at greater concentra- 
tion than Ca 2+ and binds to the polyphos- 
phoinositides with similar affinity, M f  + 
or Ca 2+ salts of the polyphosphoinosi- 
tides probably have different affinities 
for the enzymes for which they are 
substrates. 
It is alternatively possible that pro- 
ducts of phosphoinositide turnover 
trigger the rise in cell Ca 2+. For 
example, phosphatidate has been shown 
to have Ca 2+ ionophore activity, as 
have arachidonate metabolites. Another 
candidate is IP3, a product of PhlP2 
degradation. Preliminary reports indi- 
cate that IP3 can increase Ca 2+ effiux 
from cells under specified conditions 24. 
In platelets, the physiological response 
resulting from a rise in intracellular Ca 2+ 
can be mimicked by accumulation of 
DAG, this effect being mediated through 
activation of protein kinase C (Ref. 25). 
Thus, the production of both DAG and 
IP3 may be necessary for expression of a 
full response, In fact, experimentally- 
induced increases in intracellular Ca 2+ 
and DAG elicit synergistic rather than 
additive cell responses in the platelet 26. 
Inositide turnover in the nervous system 
While much of our present knowl- 
edge of the polyphosphoinositides has 
been obtained with non-neural prepara- 
tions, it is likely that the role of these 
lipids in the central nervous system will 
come under increasing scrutiny. Brain 
contains high concentrations of poly- 
phosphoinositides localized to two distinct 
pools: a metabolically stable pool asso- 
ciated with myelin and a more labile 
pool present in neuronal or glial plasma 
membranes 27. Nerve ending prepara- 
tions support a muscarinic cholinergic 
stimulation of PhA and Phi labeling, 
which has been localized post-synapti- 
cally 2~. Membranes from nerve ending 
preparations contain Ca2+-activated 
phosphodiesterase, capable of the rapid 
degradation of endogenous PhlP2 and 
PhlP 29. Although there is evidence for a 
neurotransmitter-linked effect on PhlP 
and PhIP2 turnover, direct stimulation 
of inositol lipid breakdown in the CNS 
and corresponding release of inositol 
phosphates is difficult to demonstrate. 
However, the observation by Allison et 
al. 3° that lithium administration to rats 
results in an intracerebral accumulation 
of IP1, has been successfully exploited & 
vitro. A stimulated release of IP~ can be 
detected following the addition of a 
number of neurohorulones to brain slices 
incubated in the presence of Li-  (Ref. 
56 
31). This effect of  Li + is believed to be 
due to an inhibition of  the phosphatase  
that  degrades  IPt  (Fig. 2). The increase 
in IP~ could result f rom the phosphodi-  
esteratic cleavage of  Phi ,  but recent  
evidence favors an initial release of  IP3 
(Ref.  10), followed by degradation to 
IP1 by phosphatases .  Whe the r  this 
effect of  Li ÷ can be related to its known 
psychotherapeutic  effects remains an 
open question. However ,  its use as an 
experimental  tool can be expected to 
provide much new information,  both  in 
the identification of  new neurotrans- 
mitter  systems which exert  their effects 
through inositol lipid turnover  and in 
the elucidation of  the role of  polyphos- 
phoinositides in cell-cell communica-  
tion in the brain. 
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Effects of progesterone: synergy 
and antagonism with oestrogens 
Jan Mester and Etienne-Emile Baulieu 
Progesterone and oestradiol display a complex pattern o f  actions on many bio- 
chemical parameters in their target cells. The synergy and antagonism of  the two 
hormones appear to be related to the control they exert on the concentration and 
subcellular distribution o f  their respective receptors. 
The functions of  the tissues implicated 
directly or indirectly in reproduct ion 
processes are under  the control  of  the 
sex steroid hormones .  In the female,  the 
hypothalamic and pituitary hormones  
regulate the secretion of  oestrogens and 
progesterone by the ovary; the feed- 
back by these steroids controls the pat- 
tern of sexual behaviour and repro- 
ductive capacity. 
For  the necessary fine tuning of  hor- 
monally regulated processes in the target 
tissues, the organism must  ensure that a 
response to the same stimulus at different 
t imes can be amplified or a t tenuated 
according to need.  Progesterone,  in 
Jan Mester and Etienne-Emile Baulieu are at the 
Lab. Hormones, lnserm U33, 94270 BicOtre, 
France. 
addition to the effects it exerts on the 
differentiation and function of  some 
tissues, seems to play the role of  this 
'second handle '  for the oestrogen-depen- 
dent  processes in many organs related 
to reproduct ive function in the female. 
Its antagonism of  oestrogen has long 
been  known 1, and more  recent  evidence 
demonstra tes  that the same hormone  
can potentiate ,  amplify or  sometimes 
mimic oestrogenic activity. The ampli- 
tude of  the response of  the tissue to 
progesterone depends  in turn on the 
preceding oestrogen 'priming'  of the 
tissue with resulting synthesis and ac- 
cumulation of progesterone receptors.  
In this review we summarize and analyse 
these apparently contradictory roles of 
progesterone and their possible mech- 
anisms. 
© 1984. Elsevier Science Publishers B.V.. Amsterdam1 11371~ - 5c~7 ~'$112cll 
Effect of progesterone alone 
Although the name progesterone in- 
dicates that the hormone  is necessary 
for the maintenance of  gestation, it is 
also an important factor in the regulation 
of  reproductive functions in lower 
animals such as birds and amphibians. 
All the tissues related to female repro- 
duction that have been studied possess 
intracellular proteins ( ' receptors ' )  with 
high affinity for progesterone and related 
molecules. The specificity of binding to 
progesterone receptors correlates well 
with the biological activity of the respec- 
tive compound,  supporting the hypoth- 
esis that the receptors are involved in 
the mediat ion of  hormone  action 2. 
In the absence of  hormone ,  virtually 
all progesterone receptors are recovered 
in the high-speed supernatant  fraction 
( 'cytosol ')  of  tissue homogenates ,  and 
display certain propert ies  characteristic 
o f  what  has been defined as the 'native'  
(non-activated) form. These include, in 
particular, low binding to isolated nuclei 
and to certain natural ( D N A )  or syn- 
thetic (phosphocellulose;  ATP-agarose)  
polyanions, as well as a large size indi- 
cated by a sedimentat ion coefficient of 
8S in density gradients. The actual 
progestin-binding sites are situated on 
two subunits. A (mol. wt - 79 000) and 
B (mol. wt --  110 000), which have been 
